Clinical Trial: MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07816770) titled 'MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas' on Sept. 08.

Brief Summary: This Phase II study will evaluate toripalimab plus axitinib in adults with previously untreated, synchronous metastatic non-clear cell renal cell carcinoma and renal medullary carcinomas whose primary kidney tumor remains in place and whose baseline tumor biopsy contains a tertiary lymphoid structure. All participants will receive toripalimab and axitinib for approximately 12 weeks. At Week 12, an independent multidisciplinary team will review treatment response, overall disease burden, fitn...